Here's What AstraZeneca's CEO Has to Say About the Weight Loss Drugs Market

The winners of today might not compete in the lucrative new segment of tomorrow.Industry insiders often have perspectives that are invaluable for investors to learn. In that vein, AstraZeneca's (AZN 0.75%) CEO, Pascal Soriot, recently made some interesting remarks during the company's second-quarter earnings call with analysts.Soriot's view has major implications for how investors should approach stocks like AstraZeneca, as well as weight loss drug leaders like Novo Nordisk and Eli Lilly -- not to mention b ...